78784-99-3Relevant academic research and scientific papers
TLR7 AGONISTS
-
, (2021/05/28)
The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.
Design, synthesis and SAR of potent statine-based BACE-1 inhibitors: Exploration of P1 phenoxy and benzyloxy residues
Baeck, Marcus,Nyhlen, Jonas,Kvarnstroem, Ingemar,Appelgren, Sara,Borkakoti, Neera,Jansson, Katarina,Lindberg, Jimmy,Nystroem, Susanne,Hallberg, Anders,Rosenquist, Asa,Samuelsson, Bertil
experimental part, p. 9471 - 9486 (2009/04/11)
Several BACE-1 inhibitors with low nanomolar level activities, encompassing a statine-based core structure with phenyloxymethyl- and benzyloxymethyl residues in the P1 position, are presented. The novel P1 modification introduced to allow the facile exploration of the S1 binding pocket of BACE-1, delivered highly promising inhibitors.
Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs
Johansson, Per-Ola,Chen, Yantao,Belfrage, Anna Karin,Blackman, Michael J.,Kvarnstr?m, Ingemar,Jansson, Katarina,Vrang, Lotta,Hamelink, Elizabeth,Hallberg, Anders,Rosenquist, ?sa,Samuelsson, Bertil
, p. 3353 - 3366 (2007/10/03)
Picomolar to low nanomolar inhibitors of the two aspartic proteases plasmepsin (Plm) I and II, from the malaria parasite Plasmodium falciparum, have been identified from sets of libraries containing novel statine-like templates modified at the amino and c
